| Stacey M Donegan, MD | |
|
5 Perryridge Rd, Emergency Department, Greenwich, CT 06830-4608 | |
| (203) 863-3637 | |
| (203) 863-3821 |
| Full Name | Stacey M Donegan |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Experience | 30 Years |
| Location | 5 Perryridge Rd, Greenwich, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174546709 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 044077 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Greenwich Hospital Association - | Greenwich, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Greenwich Hospital | 3678476710 | 69 |
News Archive
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Cost and quality issues in the news include research about the costliest U.S. patients, the potential that delaying aging instead of treating disease could have on extending life, and examining how the U.S. compares to other countries on approving new medical treatments.
On December 9, 2009, the United States Court of Appeals, Tenth Circuit, affirmed the federal government's position that private insurance companies are "plans" and therefore subject to federal jurisdiction.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
New research reveals bias and stereotyping among clinical and research professionals who recruit patients to enroll in cancer clinical trials. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
| Entity Name | Greenwich Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609846088 PECOS PAC ID: 3678476710 Enrollment ID: O20040128000288 |
News Archive
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Cost and quality issues in the news include research about the costliest U.S. patients, the potential that delaying aging instead of treating disease could have on extending life, and examining how the U.S. compares to other countries on approving new medical treatments.
On December 9, 2009, the United States Court of Appeals, Tenth Circuit, affirmed the federal government's position that private insurance companies are "plans" and therefore subject to federal jurisdiction.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
New research reveals bias and stereotyping among clinical and research professionals who recruit patients to enroll in cancer clinical trials. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
| Entity Name | Northeast Emergency Medicine Specialists Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982889598 PECOS PAC ID: 8729157797 Enrollment ID: O20080516000028 |
News Archive
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Cost and quality issues in the news include research about the costliest U.S. patients, the potential that delaying aging instead of treating disease could have on extending life, and examining how the U.S. compares to other countries on approving new medical treatments.
On December 9, 2009, the United States Court of Appeals, Tenth Circuit, affirmed the federal government's position that private insurance companies are "plans" and therefore subject to federal jurisdiction.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
New research reveals bias and stereotyping among clinical and research professionals who recruit patients to enroll in cancer clinical trials. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
| Entity Name | Nems Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114482882 PECOS PAC ID: 2466792833 Enrollment ID: O20190321000650 |
News Archive
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Cost and quality issues in the news include research about the costliest U.S. patients, the potential that delaying aging instead of treating disease could have on extending life, and examining how the U.S. compares to other countries on approving new medical treatments.
On December 9, 2009, the United States Court of Appeals, Tenth Circuit, affirmed the federal government's position that private insurance companies are "plans" and therefore subject to federal jurisdiction.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
New research reveals bias and stereotyping among clinical and research professionals who recruit patients to enroll in cancer clinical trials. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stacey M Donegan, MD 5 Perryridge Rd, Emergency Department, Greenwich, CT 06830-4608 Ph: (203) 863-3637 | Stacey M Donegan, MD 5 Perryridge Rd, Emergency Department, Greenwich, CT 06830-4608 Ph: (203) 863-3637 |
News Archive
Bayshore Community Hospital and Meridian Health Affiliated Foundations today announced a $5 million charitable contribution from Mrs. Janice Mitchell Vassar, whose sole desire, in her words, is to "make my hospital the best hospital it can be."
Cost and quality issues in the news include research about the costliest U.S. patients, the potential that delaying aging instead of treating disease could have on extending life, and examining how the U.S. compares to other countries on approving new medical treatments.
On December 9, 2009, the United States Court of Appeals, Tenth Circuit, affirmed the federal government's position that private insurance companies are "plans" and therefore subject to federal jurisdiction.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
New research reveals bias and stereotyping among clinical and research professionals who recruit patients to enroll in cancer clinical trials. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society.
› Verified 7 days ago
Shideh Imanian-parsa, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Perryridge Rd, Emergency Department, Greenwich, CT 06830 Phone: 203-863-3637 Fax: 203-863-3821 | |
Christopher M Davison, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5 Perryridge Rd, Emergency Department, Greenwich, CT 06830 Phone: 203-863-3637 Fax: 203-863-3821 | |
Dr. Jeremiah H Tyson, M.D Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Perryridge Rd, Greenwich, CT 06830 Phone: 203-863-3000 | |
J. Allen Britvan, M.D Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 5 Perryridge Rd, Emergency Department, Greenwich, CT 06830 Phone: 203-863-3637 Fax: 203-863-3281 | |
Michael S Canter, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5 Perryridge Rd, Emergency Department, Greenwich, CT 06830 Phone: 203-863-3632 Fax: 203-863-3821 | |
Dr. Cerrah Lynn Mendelsohn-elzam, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 7 Riversville Rd Ste 1, Greenwich, CT 06831 Phone: 203-531-1808 Fax: 203-531-8326 |